Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00174421 |
Recruitment Status :
Completed
First Posted : September 15, 2005
Last Update Posted : May 3, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Growth Disorder | Drug: Treatment with Genotropin in different dosages | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 36 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Genotropin in Short Children Born Small for Gestational Ag - A Long-Term Study in Belgium |
Study Start Date : | April 2001 |
Study Completion Date : | August 2005 |

- Final height, compared to the expected familial target height
- Body weight, body mass index at final height; adverse events and assessment of hematological and clinical chemistry

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participation in the 90-080 study
Exclusion Criteria:
- Any severe, acute or chronic disease
- Any other identifiable reason for short stature

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00174421
Study Director: | Pfizer CT.gov Call Center | Pfizer |
ClinicalTrials.gov Identifier: | NCT00174421 |
Other Study ID Numbers: |
98-8122-011 A6281219 |
First Posted: | September 15, 2005 Key Record Dates |
Last Update Posted: | May 3, 2007 |
Last Verified: | May 2007 |
Growth Disorders Pathologic Processes |